EAN Congress Masterclass, Munich

Overarching Theme of the EAN Congress Masterclass:
"Towards new standard of care for innovative treatments in autoimmune neuromuscular disorders"

The programme was put together by the EAN programme committee according to the overarching theme and shall give participants the opportunity to deepen their knowledge in this area.

For preparation purposes, participants registered to the event have to watch the corresponding congress lectures on the EAN eLearning platform.

The on-site part in Munich will begin with a welcome session, followed by four parallel masterclass sessions with rotating audiences. At the end of the event, all speakers will summarize their courses in a closing session.

General Information

To make it even more accessible, we would like to offer a limited amount of a travel and/or accommodation grant. These grants will be allocated primarily on a first-come, first-served basis, with preference given to applicants from low-income countries.

Travel grant: up to 300€ and/or accommodation grant*: one night in the hotel where the event takes place from Friday 22.11.2024 to Saturday 23.11.2024.
Travel costs will be reimbursed upon submission of an invoice and a completed reimbursement form, which will be provided at the Masterclass. The travel grants will be paid via transfer within 30 days after the event. 

You will be informed whether you will receive the travel and/or accommodation grant within one month after registration. 

* The grant is not transferable or exchangeable for any other prize and will not be paid off in cash. The decision and results concerning grant winners are final and no correspondence or discussion will be entered into after selection is made in accordance with the terms.
 

• Anna Kostera-Pruszczyk, Warsaw, Poland 
  How to manage the treatable neuromuscular diseases?
   
• Yusuf Rajabally, Birmingham, UK
  Novel diagnostic and predictive biomarkers for CIDP subgroup stratification
   
• Kristl Claeys, Leuven, Belgium
  Advances of treatments in myasthenia gravis
   
• Stephan Goedee, Utrecht, The Netherlands
  CIDP unresponsive to conventional therapies

Download agenda